Skip to main content
Premium Trial:

Request an Annual Quote

MDS Sciex, Northwestern University, Open Biosystems, Eidogen-Sertanty, NCBI, Biotrove, OpenArray, RapidFire, Evotec, Boehringer


MDS Sciex Revenues Slip 4 Percent in Fiscal Q1 as Earnings Slide

MDS Sciex this week reported that instrument sales during its fiscal first quarter declined 4 percent to $71 million from $74 million for the year-ago period.

Profits for MDS Sciex also fell to $19 million from $21 million in the first quarter of 2005, a 9.5-percent decline. The company said the decrease was "principally due to currency."

MDS said that the best-selling products in its Sciex unit were the API 5000, the 4800 MALDI/TOF/TOF, and the 3200 Qtrap.

MDS Sciex also shipped the first CellKey system produced at the new Singapore facility in the quarter. CellKey is the company's recently released cell-based assay platform based on measuring changes in electrical impedance.

Northwestern University Joins Open Biosystems' RNAi Program

Open Biosystems said this week that Northwestern University has joined its Open Access RNAi Program.

According to Open Biosystems, Northwestern's community of 270 participating research labs will have access to the company's RNAi technology through its whole-genome lentiviral shRNAmir libraries.

Financial details were not discussed.

Eidogen-Sertanty Licenses TIP to NCBI

Eidogen-Sertanty said this week that it has licensed its Target Informatics Platform to the US National Library of Medicine's National Center for Biotechnology Information.

Under the terms of the annual license, scientists at NCBI will have access to the TIP and EVE comparative visualizer.

Financial details were not released.

Biotrove Closes $7M in VC Funding to Help Sell OpenArray and RapidFire Products

Biotrove announced this week that it closed $7 million in a round of private-equity funding, bringing to $15 million its total venture capital financing since July 2005.

The round, which was oversubscribed, will help the company sell its OpenArray and RapidFire products.

Investors included Catalyst Health and Technology Partners, Echelon Ventures, Fletcher Spaght, and CB Health Ventures.

Evotec Reaches Second Discovery Milestone in Boehringer Deal

Evotec AG said this week that it has completed the second milestone in its research collaboration with Boehringer Ingelheim.

Evotec and Boehringer have collaborated since 2004.

Under the terms of the drug-discovery contract, Evotec will receive a milesont payment for an undisclosed amount, granted for the identification of a number of lead series for a priority receptor target, Evotec said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.